echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Popular Keywords > Keyword List C > car oncology

    car oncology

    Your source for diversity of car oncology articles. Discover car oncology trends, innovations and developments on echemi.com.
    • In the non-oncology field, the first domestic IND for CAR-T treatment of autoimmune diseases was accepted

      Time of Update: 2022-08-10
      They are CD19/CD22 positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and relapsed/refractory acute B-lymphocytic leukemia (B-ALL), respectively, and have been granted an "orphan drug" by the FDA Designation (ODD) In addition to CT103A, Reindeer Bio has more than 10 varieties under development at different stages of development, and its self-developed innovative product CT120 (full human CD19/CD22 dual-target CAR-T cell injection) has entered the clinical research stage.
    • Frontiers in Oncology: Two-pronged approach: chemotherapy for tumor reduction + CAR-T treatment

      Time of Update: 2021-08-26
      Frontiers in Oncology Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor BulkThe team has previously demonstrated that CAR-T therapy in refractory/relapsed B-cell acute lymphoblastic leukemia (B-ALL) is related to high treatment response and controllable toxicity after enhanced lymphocyte depletion chemotherapy .

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.